| Literature DB >> 29348805 |
Robert J Wilson1, Edgars Jecs1, Eric J Miller1, Huy H Nguyen1, Yesim A Tahirovic1, Valarie M Truax1, Michelle B Kim1, Katie M Kuo1, Tao Wang2, Chi Shing Sum2, Mary E Cvijic2, Anthony A Paiva2, Gretchen M Schroeder2, Lawrence J Wilson1, Dennis C Liotta1.
Abstract
CXCR4 is the most common chemokine receptor expressed on the surface of many cancer cell types. In comparison to normal cells, cancer cells overexpress CXCR4, which correlates with cancer cell metastasis, angiogenesis, and tumor growth. CXCR4 antagonists can potentially diminish the viability of cancer cells by interfering with CXCL12-mediated pro-survival signaling and by inhibiting chemotaxis. Herein, we describe a series of CXCR4 antagonists that are derived from (S)-5,6,7,8-tetrahydroquinolin-8-amine that has prevailed in the literature. This series removes the rigidity and chirality of the tetrahydroquinoline providing 2-(aminomethyl)pyridine analogs, which are more readily accessible and exhibit improved liver microsomal stability. The medicinal chemistry strategy and biological properties are described.Entities:
Year: 2017 PMID: 29348805 PMCID: PMC5767887 DOI: 10.1021/acsmedchemlett.7b00381
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345